Esperion Therapeutics (ESPR) Other Non-Current Liabilities (2012 - 2026)

Esperion Therapeutics has reported Other Non-Current Liabilities for 10 years, with the latest figure at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities changed N/A year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $8.7 million (changed N/A YoY), and the FY2025 full-year result was $8.7 million, changed N/A from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $8.7 million, roughly flat from $8.7 million in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $265.0 million in Q3 2022, with the low at $7.4 million in Q2 2025.
• Historically, Other Non-Current Liabilities has averaged $168.6 million across 5 years, with a median of $230.4 million in 2023.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities surged 19588.14% — and 2023, when it declined 13.08%.
• Esperion Therapeutics' Other Non-Current Liabilities stood at $218.8 million in 2022, then gained by 9.64% to $240.0 million in 2023, then slipped by 1.48% to $236.4 million in 2024, then plunged by 96.3% to $8.7 million in 2025, then changed by 0.0% to $8.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $8.7 million (Q1 2026), $8.7 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.